全文获取类型
收费全文 | 293篇 |
免费 | 24篇 |
国内免费 | 12篇 |
专业分类
儿科学 | 14篇 |
基础医学 | 9篇 |
临床医学 | 24篇 |
内科学 | 79篇 |
皮肤病学 | 3篇 |
神经病学 | 7篇 |
特种医学 | 2篇 |
外国民族医学 | 1篇 |
外科学 | 2篇 |
综合类 | 48篇 |
现状与发展 | 1篇 |
预防医学 | 1篇 |
药学 | 41篇 |
中国医学 | 8篇 |
肿瘤学 | 89篇 |
出版年
2023年 | 2篇 |
2022年 | 2篇 |
2021年 | 11篇 |
2020年 | 10篇 |
2019年 | 13篇 |
2018年 | 9篇 |
2017年 | 5篇 |
2016年 | 8篇 |
2015年 | 12篇 |
2014年 | 19篇 |
2013年 | 20篇 |
2012年 | 13篇 |
2011年 | 17篇 |
2010年 | 21篇 |
2009年 | 20篇 |
2008年 | 18篇 |
2007年 | 19篇 |
2006年 | 19篇 |
2005年 | 11篇 |
2004年 | 7篇 |
2003年 | 6篇 |
2002年 | 9篇 |
2001年 | 14篇 |
2000年 | 3篇 |
1999年 | 8篇 |
1998年 | 3篇 |
1997年 | 3篇 |
1996年 | 2篇 |
1995年 | 4篇 |
1994年 | 2篇 |
1993年 | 1篇 |
1992年 | 4篇 |
1991年 | 5篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1982年 | 1篇 |
1979年 | 1篇 |
排序方式: 共有329条查询结果,搜索用时 15 毫秒
1.
Xinping Zhou Chen Mei Jin Zhang Ying Lu Jianping Lan Shengyun Lin Yuefeng Zhang Yuemin Kuang Yanling Ren Liya Ma Juying Wei Li Ye Weilai Xu Kongfei Li Chenxi Lu Jie Jin Hongyan Tong 《Hematological oncology》2020,38(4):531-540
Patients with acute myeloid leukemia (AML) evolving from myelodysplastic syndrome (MDS) or higher-risk MDS have limited treatment options and poor prognosis. Our previous single-center study of decitabine followed by low dose idarubicin and cytarabine (D-IA) in patients with myeloid neoplasms showed promising primary results. We therefore conducted a multicenter study of D-IA regimen in AML evolving from MDS and higher-risk MDS. Patients with AML evolving from MDS or refractory anemia with excess blasts type 2 (RAEB-2) (based on the 2008 WHO classification) were included. The D-IA regimen (decitabine, 20 mg/m2 daily, days 1 to 3; idarubicin, 6 mg/m2 daily, days 4 to 6; cytarabine 25 mg/m2 every 12 hours, days 4 to 8; granulocyte colony stimulating factor [G-CSF], 5 μg/kg, from day 4 until neutrophil count increased to 1.0 × 109/L) was administered as induction chemotherapy. Seventy-one patients were enrolled and treated, among whom 44 (62.0%) had AML evolving from MDS and 27 (38.0%) had RAEB-2. Twenty-eight (63.6%) AML patients achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi): 14 (31.8%) patients had CR and 14 (31.8%) had CRi. Six (22.2%) MDS patients had CR and 15 (55.6%) had marrow complete remission. The median overall survival (OS) was 22.4 months for the entire group, with a median OS of 24.2 months for AML and 20.0 months for MDS subgroup. No early death occurred. In conclusion, the D-IA regimen was effective and well tolerated, representing an alternative option for patients with AML evolving from MDS or MDS subtype RAEB-2. 相似文献
2.
Erika Borlenghi Chiara Cattaneo Elisa Cerqui Silvana Archetti Diego Bertoli Daniela Bellotti Doriana Gramegna Giulia Soverini Margherita Oberti Francesca Schieppati Chiara Pagani Angela Passi Margherita Sciumé Mirko Farina Cecilia Carbone Claudia Crippa Daniela Dalceggio Alessandra Tucci Giuseppe Rossi 《Hematological oncology》2020,38(5):754-762
Consolidation treatment in acute myeloid leukemia (AML) patients achieving complete remission (CR) is warranted. High-dose cytarabine (HDAC) is considered first choice in favorable risk and an option in intermediate-risk AML. However, its optimal dose and schedule, as well as the benefit of additional chemotherapy agents remain controversial. Herein, we report on the long-term outcome of consecutive unselected AML patients treated with repeated courses of HDAC, with the addition of idarubicin, followed by autologous peripheral blood stem cell (PBSC) support, in order to limit toxicity, according to Northern Italy Leukemia Group (NILG) AML-01/00 study (EUDRACT number 00400673). Among 338 patients consecutively diagnosed from 2001 to 2017 at our center, 148 with high-risk AML (adverse cytogenetic, isolated FLT3-internal tandem duplication mutation, refractory to first induction) were addressed to allogeneic stem cell transplant. All other cases, 186 patients (55%), median age 53 (range 19–75), were considered standard-risk and received the NILG AML-01/00 program. After achieving CR, patients were mobilized with cytarabine 8 g/sqm to collect autologous CD34+-PBSC and received three consolidation cycles with HDAC (20 g/sqm) plus idarubicin (20 mg/sqm) per cycle, followed by reinfusion of limited doses of CD34+ PBSC (1-2x106/kg). The program was completed by 160 (86%) patients. Toxicity was acceptable. Neutrophils recovered a median of 10 days. Treatment-related mortality was 3/160 (1.8%). After a median follow-up of 66.4 months, overall survival (OS) and relapse-free survival (RFS) at 5-years were 61.4% and 52.4%, respectively. Twenty-eight selected patients aged >65 had similar outcomes. According to European leukemia net-2010 classification, the OS and RFS at 5-years were 76.4% and 65% in favorable risk, without differences between molecular subgroups, 52.3% and 47.2% in Intermediate-I, 45.2% and 36.5% in Intermediate-II risk patients, respectively. In conclusion, consolidation including repeated courses of high dose cytarabine and idarubicin, with limited PBSC support, proved feasible and very effective in nonhigh risk patients. The incorporation of novel agents in its backbone may be tested to further improve patient's prognosis. 相似文献
3.
Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine,fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older 下载免费PDF全文
4.
《中国现代医生》2021,59(29):113-116+121
目的 分析慢性粒细胞白血病患者采用小剂量干扰素联合阿糖胞苷治疗的临床效果。方法 将2017 年1 月至2018 年12 月我院收治的100 例慢性粒细胞白血病患者纳入此次研究,采取随机分组法将100 例患者分为两组,对照组(n=50)采取阿糖胞苷进行治疗,观察组(n=50)采取小剂量干扰素联合阿糖胞苷进行治疗,观察两组患者总有效率、血液学缓解时间、细胞遗传学缓解时间、不良反应发生率及治疗前后白细胞水平、生活质量评分。结果 观察组临床有效率、血液学缓解时间及细胞遗传学缓解时间均显著优于对照组,差异有统计学意义(P<0.05);治疗后,观察组白细胞水平均显著低于对照组,差异有统计学意义(P<0.05);观察组躯体功能、心理功能、社会认知、认知功能及总体生活质量评分均显著高于对照组,差异有统计学意义(P<0.05)。结论 采用小剂量干扰素联合阿糖胞苷治疗慢性粒细胞白血病,可缩短患者血液学缓解时间、细胞遗传学缓解时间,使患者生存时间得以延长,且不良反应较少,临床效果显著。 相似文献
5.
Autophagy is an important mechanism involved in the regulation of acute myeloid leukemia (AML) chemoresistance. The long noncoding RNA (lncRNA) differentiation antagonizing non‐protein coding RNA (DANCR) exhibits oncogenic activity in several types of human cancers, including AML, but it remains unclear whether it regulates autophagy and chemoresistance in AML. We report here that cytarabine (Ara‐C) treatment elevates DANCR expression in human AML cells. In addition, DANCR overexpression confers and its knockdown diminishes Ara‐C resistance in human AML cells, suggesting that DANCR positively regulates AML chemoresistance to Ara‐C. Moreover, DANCR promotes autophagy in Ara‐C‐treated human AML cells and acts as a sponge to decrease miR‐20a‐5p expression, thereby upregulating the expression of ATG16L1, a critical component of the autophagy machinery. Importantly, ATG16L1 silencing abrogates DANCR‐promoted autophagy and markedly restores DANCR‐conferred Ara‐C resistance, suggesting that DANCR promotes MIR‐874‐3P/ATG16L1 axis‐regulated autophagy to confer Ara‐C resistance in human AML cells. Together, this study identifies DANCR as a positive regulator of Ara‐C resistance in human AML cells, suggesting this lncRNA as a potential target for overcoming Ara‐C resistance in AML chemotherapy. 相似文献
6.
Susana Vives MD David Martínez-Cuadrón MD Juan Bergua Burgues MD Lorenzo Algarra MD Mar Tormo MD María Pilar Martínez-Sánchez MD Josefina Serrano MD Pilar Herrera MD Fernando Ramos MD Olga Salamero MD Esperanza Lavilla MD José L. López-Lorenzo MD Cristina Gil MD Belén Vidriales MD Jose F. Falantes MD Alfons Serrano MD Jorge Labrador MD María J. Sayas MD María Á. Foncillas MD María L. Amador Barciela MD María Teresa Olave MD Mercedes Colorado MD Adriana Gascón MD María Á. Fernández MD Adriana Simiele MD Manuel M. Pérez-Encinas MD Rebeca Rodríguez-Veiga MD Olga García MS Joaquín Martínez-López MD Eva Barragán PhD Bruno Paiva PhD Miguel Á. Sanz MD Pau Montesinos MD for the PETHEMA Group 《Cancer》2021,127(12):2003-2014
7.
Rui Chen MD Bin Ma MD Kehu Yang MD Jinhui Tian MD Yali Liu MD Li Zhao MD PhD 《Current therapeutic research》2011,72(4):150-163
Objective
This article compares the effect of interferon alfa plus cytarabine (IFN-alfa + Ara-C) versus IFN-alfa alone on the chronic phase of chronic myelogenous leukemia.Methods
Electronic searches were performed in the Cochrane Central Register of Controlled Trials, PubMed, EMBASE, Chinese Biomedical Database, China Journal Full-text Database, and Chinese Scientific Journals Database. The languages were limited to Chinese and English. Randomized controlled trials were selected by 2 investigators. Analyses were performed using RevMan 5.0 software.Results
A total of 3139 patients in 4 studies met the inclusion criteria. In those patients, complete hematologic response and cytogenetic responses showed significant improvements in favor of IFN-alfa + Ara-C, with complete hematologic response relative risk (RR) of 1.15 (95% CI, 1.09–1.21), complete cytogenetic response RR of 1.87 (95% CI, 1.47–2.38), partial cytogenetic response RR of 1.48 (95% CI, 1.25–1.75), and major cytogenetic response RR of 1.61 (95% CI, 1.42–1.83), respectively. The overall 3-year survival rate in the IFN-alfa + Ara-C group was 86% compared with 79% in the IFN-alfa group (RR = 1.09; 95% CI, 1.03–1.14). In the other 2 studies, 5-year overall survival was 69% compared with 63%, respectively (RR = 1.08; 95% CI, 1.01–1.15). However, IFN-alfa and Ara-C involved higher risk of hematologic toxicity, gastrointestinal adverse events, and severe mucositis compared with IFN-alfa monotherapy (RR = 2.63 [95% CI, 1.94–3.56); RR = 3.38 [95% CI, 2.28–5.00], and RR = 8.84 [95% CI, 3.82–20.46], respectively). Weight loss and skin rash were also observed more frequently in the combination treatment group (RR = 2.00 [95% CI, 1.47–2.73) and RR = 3.75 [95% CI, 2.13–6.59], respectively).Conclusions
In patients with chronic myelogenous leukemia in the chronic phase, the combination of IFN-alfa + Ara-C demonstrated improved complete hematologic response, superior cytogenetic responses, and higher rates of 3- and 5-year survival than IFN-alfa alone. However, combination therapy is more likely to cause serious adverse effects. Well-designed studies will be required to determine the outcomes and adverse effects of the 2 drugs as treatment for patients with chronic myelogenous leukemia who cannot afford molecularly targeted drugs. 相似文献8.
Boula AM Mantadakis E Xilouri IM Christoforidou AV Foudoulakis AM Samonis G 《American journal of hematology》2005,79(3):216-219
A unique case of a 72-year-old man with chronic myelomonocytic leukemia (CMML) who developed hepatic veno-occlusive disease (VOD) after treatment with a single dose of vincristine and standard doses of cytarabine is described. Unexpected peroneal nerve palsy suggestive of vincristine neurotoxicity occurred concurrently and pointed to vincristine as the most likely cause of the VOD. To the best of our knowledge, association between vincristine and hepatic VOD has not been previously described in chemotherapy-naive patients with CMML. 相似文献
9.
Rupa Narayan MD Traci M. Blonquist MS Ashkan Emadi MD PhD Robert P. Hasserjian MD Meghan Burke BS Christopher Lescinskas BS Donna S. Neuberg ScD Andrew M. Brunner MD Gabriela Hobbs MD Hanno Hock MD PhD Steven L. McAfee MD Yi-Bin Chen MD Eyal Attar MD Timothy A. Graubert MD Christina Bertoli MSN Jenna A. Moran MSN Meghan K. Bergeron MSN Julia E. Foster MSN Aura Y. Ramos BSN Tina T. Som BSN Megan K. Vartanian BSN RN Jennifer L. Story LPN Kristin McGregor MS Molly Macrae BS Tanya Behnan BS Margaret C. Wey PhD Jessica Rae BSN Frederic I. Preffer PhD Patricia Lesho BA Vu H. Duong MD Mason L. Mann BA Karen K. Ballen MD Christine Connolly BS Philip C. Amrein MD Amir T. Fathi MD 《Cancer》2020,126(6):1264-1273